Hepatocellular Carcinoma (BCLC Stage B): What to Do When TACE or TARE Did Not Achieve Objective Response

In intermediate-stage hepatocellular carcinoma (BCLC Stage B), locoregional therapy is the established first-line approach. When it fails to reach its imaging response target, a defined evidence-based next step applies.

Clinical Scenario

Hepatocellular carcinoma at BCLC Stage B (intermediate stage) in a patient who has undergone locoregional therapy and has not achieved the required objective tumor response.

Prior Treatment — Failure Condition

First-line locoregional therapy — transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) — did not meet its treatment goal: no definite viable disease on multiphase CT or contrast-enhanced MRI at the expected post-treatment imaging assessment. This protocol defines the recommended next step after that failure.

Next-Line Approach (Partial Overview)

For patients with intermediate-stage HCC who are unsuitable for or refractory to locoregional therapy, systemic therapy is recommended. The full protocol specifies which regimens are preferred and the conditions under which each applies — access the complete structured regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/HEP.0000000000000466

Patients with BCLC Stage B HCC should be treated with transarterial chemoembolization (Level 1, Strong Recommendation).

AASLD advises systemic therapy in patients with intermediate HCC who are unsuitable for or refractory to locoregional therapies due to contraindications, worsening hepatic dysfunction, progression of HCC, or lack of objective response (Level 3, Strong Recommendation).

Patients with advanced HCC who have Child-Turcotte-Pugh A cirrhosis should be offered atezolizumab plus bevacizumab or durvalumab plus tremelimumab as preferred first-line therapy options (Level 2, Strong Recommendation).

View source ↗